LEADER 05410nam 2200649 450 001 9910788052603321 005 20230807204751.0 010 $a1-61705-222-1 035 $a(CKB)2670000000592144 035 $a(EBL)1938227 035 $a(SSID)ssj0001420989 035 $a(PQKBManifestationID)12540328 035 $a(PQKBTitleCode)TC0001420989 035 $a(PQKBWorkID)11404056 035 $a(PQKB)10257878 035 $a(MiAaPQ)EBC1938227 035 $a(Au-PeEL)EBL1938227 035 $a(CaPaEBR)ebr11016332 035 $a(CaONFJC)MIL718637 035 $a(OCoLC)902725071 035 $a(EXLCZ)992670000000592144 100 $a20150218h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCytopathology case reviews /$fChristopher J. VandenBussche and Syed Z. Ali ; acquisitions editor, Rich Winters 210 1$aNew York, New York :$cDemos Medical,$d2015. 210 4$dİ2015 215 $a1 online resource (271 p.) 300 $aDescription based upon print version of record. 311 $a1-322-87355-0 311 $a1-62070-059-X 320 $aIncludes bibliographical references and indexes at the end of each chapters. 327 $aCover; Title; Copyright; Contents; Foreword; Preface; Share Cytopathology Case Review; Case 1: Fluid Pericardium; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; b. Hodgkin Lymphoma; References; Case 2: FNA Thyroid; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; b. Medullary Thyroid Carcinoma; References; Case 3: Pap test Cervix; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; e. ASC-US and AGC; References; Case 4: Fluid Abdomen; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion 327 $ab. Pleomorphic RhabdomyosarcomaReference; Case 5: FNA Lymph node; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; e. Metastatic Renal Cell Carcinoma; Reference; Case 6: FNA Breast; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; d. Ductal Carcinoma With Mucinous Features; References; Case 7: Urine Bladder; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; a. Carcinoma With Extensive Squamous Differentiation; References; Case 8: FNA Lung; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion 327 $ab. Metastatic Malignant MelanomaReferences; Case 9: FNA Liver; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; e. Poorly Differentiated Hepatocellular Carcinoma (HCC); Reference; Case 10: FNA Pleura; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; c. Malignant Mesothelioma; Reference; Case 11: FNA Bone; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; b. Large Cell Lymphoma; References; Case 12: Pap test Cervix; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion 327 $aa. Squamous Cell Carcinoma of the CervixReference; Case 13: FNA Stomach; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; b. Gastrointestinal Stromal Tumor (GIST); Reference; Case 14: FNA Pancreas; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; a. Well-Differentiated Pancreatic Neuroendocrine Tumor (PanNET); Reference; Case 15: FNA Soft tissue; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; b. Ulcerating Tuberculous Infection (Scrofula); References; Case 16: FNA Salivary; Clinical History; Choose the Best Diagnosis 327 $aAnswer and Brief Discussionc. Pleomorphic Adenoma; References; Case 17: FNA Liver; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; d. Consistent With Focal Nodular Hyperplasia; References; Case 18: FNA Thyroid; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; c. Consistent With Graves' Disease; References; Case 19: FNA Soft tissue; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion; d. Schwannoma; References; Case 20: FNA Salivary; Clinical History; Choose the Best Diagnosis; Answer and Brief Discussion 327 $ad. Mucoepidermoid Carcinoma (MEC), High Grade 330 $aPathology residents, fellows, and practitioners will welcome this cytopathology review of carefully selected case scenarios drawn from the Johns Hopkins case archive. Each illustrated case scenario contains multiple-choice questions along with detailed explanations and references. Authored by distinguished faculty at Johns Hopkins University, the helpful review covers all major topics within cytopathology. Each clinical case scenario includes representative images and clinical history, diagnostic question, and detailed discussion supported by thoughtfully selected key references. Cases are pres 606 $aCytodiagnosis$vCase studies 606 $aPathology, Cellular$vCase studies 615 0$aCytodiagnosis 615 0$aPathology, Cellular 676 $a616.07/582 700 $aVandenBussche$b Christopher J.$01085144 702 $aAli$b Syed Z. 702 $aWinters$b Rich 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910788052603321 996 $aCytopathology case reviews$93771155 997 $aUNINA LEADER 05659nam 2200769 a 450 001 9910876778503321 005 20200520144314.0 010 $a9781523111251 010 $a1523111259 010 $a9781118448205 010 $a1118448200 010 $a9781118448267 010 $a111844826X 010 $a9781283869195 010 $a1283869195 010 $a9781118448274 010 $a1118448278 035 $a(CKB)2550000000709521 035 $a(EBL)1093955 035 $a(OCoLC)823387194 035 $a(SSID)ssj0000784678 035 $a(PQKBManifestationID)11435817 035 $a(PQKBTitleCode)TC0000784678 035 $a(PQKBWorkID)10784423 035 $a(PQKB)10131973 035 $a(MiAaPQ)EBC1093955 035 $a(Perlego)1000214 035 $a(EXLCZ)992550000000709521 100 $a20120731d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAdvances in dairy ingredients /$fedited by Geoffrey W. Smithers, Mary Ann Augustin 210 $aAmes, Iowa $cJohn Wiley & Sons $cInstitute of Food Technologists$d2013 215 $a1 online resource (351 p.) 225 0 $aInstitute of Food Technologists series 300 $aDescription based upon print version of record. 311 08$a9780813823959 311 08$a0813823951 320 $aIncludes bibliographical references and index. 327 $aTitle page; Copyright page; Titles in the IFT Press series; Contents; Contributors; Preface; 1: Dairy Protein Powders; 1.1 Introduction; 1.2 Extraction of Milk Proteins; 1.2.1 Milk proteins; 1.2.2 Separation of proteins; 1.2.3 Pretreatment of milk; 1.3 Drying Principles; 1.3.1 Roller drying; 1.3.2 Spray drying and fluid bed drying/cooling; 1.4 Drying of Dairy Proteins; 1.4.1 Heat treatment; 1.4.2 Water transfer; 1.4.3 Energy consumption; 1.5 Powder Properties; 1.5.1 Powder structure; 1.5.2 Particle size distribution; 1.5.3 Powder density; 1.5.4 Flowability 327 $a1.5.5 Rehydration of dairy protein powders1.6 Conclusion; References; 2: Lactose: Chemistry, Processing, and Utilization; 2.1 Introduction; 2.2 Forms and Properties of Lactose; 2.2.1 Types of lactose; 2.2.2 Mutarotation; 2.2.3 Solubility and supersaturation; 2.2.4 Properties of lactose crystals; 2.3 Manufacture of Lactose; 2.3.1 Industrial processes for ?-lactose monohydrate; 2.3.2 Creation of amorphous lactose during the ?-lactose monohydrate manufacturing process; 2.3.3 Crystallization theory and research trends; 2.3.4 Effect of impurities on lactose crystal growth 327 $a2.4 Effect of Moisture on Lactose in the Solid State2.4.1 Moisture-induced crystallization of amorphous lactose; 2.4.2 Effect of moisture on the crystalline forms of lactose; 2.4.3 Effect of moisture and amorphous lactose content in lactose-rich dairy powders; 2.5 Lactose Applications; 2.6 Summary; References; 3: Dairy Ingredients Containing Milk Fat Globule Membrane: Description, Composition, and Industrial Potential; 3.1 Introduction; 3.2 Origin and Function of the MFGM; 3.3 Composition and Structure of the MFGM; 3.3.1 Lipids of the milk fat globule membrane 327 $a3.3.2 Milk fat globule membrane proteins3.4 Health Benefits of the Milk Fat Globule Membrane; 3.4.1 Anticancer properties of MFGM; 3.4.2 Antimicrobial and antiviral properties of the MFGM; 3.4.3 MFGM and lactic acid bacteria binding; 3.5 Technical Aspects and Foods Based on MFGM; 3.5.1 Emulsifying and stabilizing properties of MFGM; 3.5.2 Potential delivery systems derived from MFGM; 3.5.3 MFGM components as part of food systems; 3.5.4 Isolation of the MFGM; 3.6 MFGM: A Novel Product from Dairy Products 327 $a3.7 Methodology to Monitor the Biological Activity of the MFGM Before and After Processing3.7.1 Atomic force microscopy; 3.7.2 Confocal laser scanning microscopy; 3.7.3 Laser tweezers and the MFGM; 3.8 The Future of MFGM and Its Components; Acknowledgments; References; 4: Biofunctional Dairy Protein Fractions; 4.1 Introduction; 4.2 Physiologically Active Peptides from Milk; 4.2.1 Antihypertensive peptides; 4.2.2 Biological role of antithrombotic peptides; 4.2.3 Biological role of immunomodulatory peptides; 4.2.4 Biological role of opioid receptor-binding peptides 327 $a4.2.5 Biological role of metal-binding peptides 330 $aAdvances in Dairy Ingredients provides an international perspective on recent developments in the area of dairy ingredients and dairy technology. Market and manufacturing trends and opportunities are aligned with the latest science tools that provide the foundation to successfully and rapidly capture these opportunities. Functional foods are emerging as key drivers of the global food economy and dairy ingredients and technology are at the forefront in these developments. Advances in Dairy Ingredients brings together food scientists, industry specialists, and marketers from around 410 0$aInstitute of Food Technologists Series 606 $aDairy products industry$xTechnological innovations 606 $aMilk trade$xTechnological innovations 606 $aDairy processing 615 0$aDairy products industry$xTechnological innovations. 615 0$aMilk trade$xTechnological innovations. 615 0$aDairy processing. 676 $a636.2/142 701 $aSmithers$b Geoffrey W$01761404 701 $aAugustin$b M. A$01761405 712 02$aInstitute of Food Technologists. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910876778503321 996 $aAdvances in dairy ingredients$94200835 997 $aUNINA